ProQR Therapeutics B.V. Announces Results For The Third Quarter Of 2014

LEIDEN, the Netherlands, Nov. 24, 2014 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), an innovative biopharmaceutical company engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, today announced results for the third quarter of 2014.

"ProQR has made significant accomplishments, both financially and operationally, in 2014," said Daniel de Boer, Chief Executive Officer of ProQR. "With the successful completion of our recent initial public offering, we have strengthened our balance sheet, which will allow us to advance the clinical development of QR-010 for the treatment of patients with cystic fibrosis and continue to build our platform and pipeline of proprietary programs."

Financial Highlights

Net cash generated by financing activities during the three and nine months ended September 30, 2014 was €80.2 million and €119.7 million, respectively.

To read full press release, please click here.

Help employers find you! Check out all the jobs and post your resume.